E Santagostino
Overview
Explore the profile of E Santagostino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
138
Citations
1518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reipert B, Gangadharan B, Hofbauer C, Berg V, Schweiger H, Bowen J, et al.
Blood Adv
. 2020 Nov;
4(22):5785-5796.
PMID: 33232473
Preventing factor VIII (FVIII) inhibitors following replacement therapies with FVIII products in patients with hemophilia A remains an unmet medical need. Better understanding of the early events of evolving FVIII...
2.
Castaman G, Borchiellini A, Santagostino E, Radossi P, Aksu S, Yilmaz M, et al.
Eur J Pharm Sci
. 2020 Jul;
153:105485.
PMID: 32712218
Background: An open-label phase II, multicenter clinical trial was conducted at 11 Haemophilia Centres in Italy, Romania, and Turkey, to evaluate the pharmacokinetics (PK), efficacy, and safety of high purity,...
3.
Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis
Carcao M, Lambert T, Leissinger C, Escuriola-Ettingshausen C, Santagostino E, Aledort L
Haemophilia
. 2018 Jul;
24(6):845-848.
PMID: 29989273
No abstract available.
4.
Hermans C, Mahlangu J, Booth J, Schutz H, Santagostino E, Young G, et al.
Haemophilia
. 2018 May;
24(3):376-384.
PMID: 29732708
Introduction: Currently, no universally accepted definition of extended half-life (EHL) recombinant FVIII (rFVIII) exists. Identifying the minimum half-life extension ratio required for a reduction in dosing frequency compared with standard...
5.
Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E
Haemophilia
. 2018 Apr;
24(3):348-358.
PMID: 29633467
Introduction: Recent haemophilia treatment advances include new recombinant FVIII (rFVIII) products with improved pharmacokinetic (PK) properties that aim to reduce the burden of prophylaxis. These treatments are commonly referred to...
6.
Marchesini E, Oliovecchio E, Coppola A, Santagostino E, Radossi P, Castaman G, et al.
Haemophilia
. 2017 Dec;
24(1):e6-e10.
PMID: 29271531
No abstract available.
7.
Khair K, Mazzucconi M, Parra R, Santagostino E, Tsakiris D, Hermans C, et al.
Haemophilia
. 2017 Oct;
24(1):85-96.
PMID: 29044825
Introduction: Outcome data on treatment of patients with haemophilia A spanning several years of real-world evidence collection are currently very limited. Aim And Methods: The global prospective long-term Advate Haemophilia...
8.
Boccalandro E, Mancuso M, Riva S, Pisaniello D, Ronchetti F, Santagostino E, et al.
Haemophilia
. 2017 Aug;
24(1):57-62.
PMID: 28780767
Introduction: Persons with haemophilia (PWH) born before the middle 1970s have spent a substantial part of their lives without the benefits of replacement therapy, that became available on a relative...
9.
Cugno M, Mancuso M, Tedeschi A, Santagostino E, Lorini M, Carbonelli V, et al.
Haemophilia
. 2017 Jun;
23(4):e348-e353.
PMID: 28594432
Introduction: Patients with haemophilia B who develop factor IX (FIX) neutralizing antibodies (inhibitors) after FIX infusion are at high risk of hypersensitivity reactions upon FIX re-exposure, but the underlying mechanisms...
10.
Riva S, Mancuso M, Cortesi L, Nobili A, Santagostino E, Peyvandi F, et al.
Haemophilia
. 2017 May;
24(1):e1-e3.
PMID: 28544483
No abstract available.